Novo Nordisk (NYSE:NVO) announced that one of its contract manufacturers filling syringes for its Wegovy (semaglutide) pens in the U.S. market has temporarily ceased manufacturing following a report of Good Manufacturing Practice (GMP) problems. The company projects it will be unable to meet U.S. demand for the drug in the first half of 2022 and…